A company rich in history, yet poised for the future.

Indivior began with the goal of addressing the lack of treatment for the worldwide problem of addiction. In 1994, RB established the Buprenorphine Business Group, to which Indivior can trace its history of over 20 years. The buprenorphine Business Group focused on developing buprenorphine for the treatment of opioid dependence. Even though it was an area of business that was unproven, we believed we could make a measurable difference in the lives of patients all over the world. Through a grassroots effort, we’ve partnered with and educated governments, policy makers, payers, and healthcare professionals about diseases of addiction and the value of alternative treatment options (including office-based treatment). We’ve also worked diligently and strategically to identify and address the unmet treatment needs of patients.

We’re proud of our history but, more than that, we’re excited about our future.

Prescribing information for Indivior products available upon request.

Indivior History Highlights.
1994

Buprenorphine Business Group established by Reckitt Benckiser to develop buprenorphine for the treatment of opioid dependence

1995

SUBUTEX® (buprenorphine) approved for treatment of opioid dependence in general medical practice by ANSM (France)

2000

In US, Drug Abuse Treatment Act of 2000 legislation permitted qualified physicians to prescribe and dispense specifically approved Schedule III, IV and V narcotic medications for the treatment of opioid dependence in settings other than an opioid treatment program

2002

FDA approves SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) and SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII) for treatment of opioid dependence in USA

2002

Reckitt Benckiser Pharmaceuticals launches SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CIII) and SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) in USA

2006

SUBOXONE sublingual tablet granted marketing authorization by European Commission

2007

DATA 2000 (US) cap was extended from 30 to 100 patients for physicians with at least one year's clinical experience with buprenorphine

2008

Acquired SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) rights from Monosol RX under licence

2010

Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in US

2011

Discontinuation of SUBUTEX® (buprenorphine) Sublingual Tablet (CIII) in US

2011

Launch of SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CIII) in Australia

2011

Discontinuation of SUBUTEX sublingual tablet announced in US

2013

SUBOXONE approved in Malaysia

2014

SUBOXONE film approved for use in both induction and maintenance treatment of opioid dependence in appropriate patients

2014

February 2014, the Indivior entered into an agreement with AntiOp, Inc. to co-develop a naloxone nasal spray to aid in the reversal of opioid overdose with the option to acquire all rights to the product upon receipt of regulatory and marketing approval

2014

May 2014, Indivior entered into a global licensing agreement with XenoPort, Inc. for the development and commercialization of a clinical-stage oral product candidate called arbaclofen placarbil for the treatment of alcohol use disorder

2014

September - Indivior PLC incorporated

2014

December 23rd - Demerger of Reckitt Benckiser Pharmaceuticals Inc. from RB Group; listing as Indivior PLC on London Stock Exchange

2015

EU approved SUBOXONE tablet 16mg/4mg strengths

2017

NALSCUE® naloxone nasal spray received marketing authorization from ANSM (France)

2017

FDA Approves SUBLOCADE™ (Buprenorphine Extended-Release), the First and Only Once-Monthly Injectable Buprenorphine Formulation to Treat Moderate to Severe Opioid Use Disorder

2017

Indivior Announces NDA Acceptance of RBP-7000 Risperidone Monthly Depot

2018

Indivior and Addex Enter Strategic Collaboration to Accelerate Development of GABAB PAMs for Addiction Disorder Treatments

2018

SUBLOCADE™ becomes available in the US